Viewed: 113
Emailed: 0
PDF Downloaded: 349
Full Text PDF Share on Facebook Share on Twitter
Original Article
Author Details :
Volume : 14, Issue : 1, Year : 2024
Article Page : 216-221
https://10.18231/j.pjms.2024.039
Abstract
Background: Musculoskeletal conditions are the most common cause of long-term pain and physical disability. The burden of musculoskeletal conditions is not only in terms of global numbers but also in terms of physical and psychosocial disability. Pain arising from musculoskeletal conditions of the major joints like back, neck, shoulder, knee or multi-site involvement results in diminished quality of life. Evidence for the effectiveness and safety of the various drugs used to alleviate MSP is uncertain.
Materials and Methods: The present study was an observational, cross-sectional study which included patients with complaints of musculoskeletal pain attending Regional Spine Injury Centre, S.C.B Medical College and Hospital. A total of 100 patients were included in the study. Demographic data of all the patients was collected and their level of significance in the causation of musculoskeletal pain was assessed. The prescription pattern of the drugs for musculoskeletal pain was analysed. All the patients taking the drugs were monitored for any adverse drug reaction and the same was documented.
Conclusion: Low back ache (28%) was the most common type of musculoskeletal pain observed. Aceclofenac was the most common analgesic prescribed, followed by paracetamol and etoricoxib. Aceclofenac and paracetamol was the most common combination used. Pain abdomen was the most common ADR encountered.
Keywords: Aceclofenac, Low back ache, Musculoskeletal pain
How to cite : Upadhyay R, Upadhyay M, Misra P, Palai S, Study of utilisation pattern and adverse reaction monitoring of drugs used for relief of musculoskeletal pain in a tertiary care teaching hospital in Eastern Odisha. Panacea J Med Sci 2024;14(1):216-221
Copyright © 2024 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)